These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4627781)

  • 1. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone.
    Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC
    Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
    Huidobro-Toro JP; De Carolis AS; Longo VG
    Pharmacol Biochem Behav; 1974; 2(1):105-9. PubMed ID: 4364044
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyrotropin releasing hormone: enhancement of DOPA activity in thyroidectomized rats.
    Plotnikoff NP; Prange AJ; Breese GR; Wilson IC
    Life Sci; 1974 Apr; 14(7):1271-8. PubMed ID: 4207315
    [No Abstract]   [Full Text] [Related]  

  • 5. Thyrotropin releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP; Breese GR; Prange AJ
    Pharmacol Biochem Behav; 1975; 3(4):665-70. PubMed ID: 810812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).
    Plotnikoff NP; Kastin AJ; Anderson MS; Schally AV
    Life Sci I; 1971 Nov; 10(22):1279-83. PubMed ID: 4947365
    [No Abstract]   [Full Text] [Related]  

  • 7. TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats.
    Green AR; Grahame-Smith DG
    Nature; 1974 Oct; 251(5475):524-6. PubMed ID: 4214262
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth hormone release inhibiting hormone: neuropharmacological studies.
    Plotnikoff NP; Kastin AJ; Schally AV
    Pharmacol Biochem Behav; 1974; 2(5):693-6. PubMed ID: 4610595
    [No Abstract]   [Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone and thyrotropin-releasing hormone: distribution and effects in the central nervous system.
    Wilber JF; Montoya E; Plotnikoff NP; White WF; Gendrick R; Renaud L; Martin JB
    Recent Prog Horm Res; 1976; 32():117-59. PubMed ID: 822482
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional evaluation of prolactin secretion: a guide to therapy.
    Friesen H; Guyda H; Hwang P; Tyson JE; Barbeau A
    J Clin Invest; 1972 Mar; 51(3):706-9. PubMed ID: 4622109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRH protection against memory retrieval deficits is independent of endocrine effects.
    Stwertka SA; Vincent GP; Gamzu ER; MacNeil DA; Verderese AG
    Pharmacol Biochem Behav; 1992 Jan; 41(1):145-52. PubMed ID: 1539064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the central nervous system effects of DOPA by decarboxylase inhibition: possible direct role of this neuroamino acid in brain mechanisms.
    Vazquez AJ; Sabelli HC
    Exp Neurol; 1975 Jan; 46(1):44-56. PubMed ID: 1109342
    [No Abstract]   [Full Text] [Related]  

  • 15. Proceedings: Neurotropic effects of thyrotropin releasing hormone (TRH).
    Kruse H
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R51. PubMed ID: 4276591
    [No Abstract]   [Full Text] [Related]  

  • 16. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of thyroid stimulating hormone from chick anterior pituitary glands by thyrotropin releasing hormone (TRH).
    Breneman WR; Rathkamp W
    Biochem Biophys Res Commun; 1973 May; 52(1):189-94. PubMed ID: 4197189
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaco-behavioral effects of hypothalamic peptides in animals and man: focus on thyrotropin-releasing hormone and neurotensin.
    Nemeroff CB; Loosen PT; Bissette G; Manberg PJ; Wilson IC; Lipton MA; Prange AJ
    Psychoneuroendocrinology; 1978 Oct; 3(3-4):279-310. PubMed ID: 34843
    [No Abstract]   [Full Text] [Related]  

  • 19. DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide.
    Plotnikoff NP; Minard FN; Kastin AJ
    Neuroendocrinology; 1974; 14(5):271-9. PubMed ID: 4858836
    [No Abstract]   [Full Text] [Related]  

  • 20. Prolactin and thyrotropin responses to thyrotropin-releasing hormone during the peripartal period.
    Miyamoto J
    Obstet Gynecol; 1984 May; 63(5):639-44. PubMed ID: 6425749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.